About G-NiiB
G-NiiB is a company based in Hong Kong (China) founded in 2020. It operates as a B2B. G-NiiB operates in a competitive market with competitors including Inflammatix, MeMed, Geneoscopy, Pendulum and GenMark Diagnostics, among others.
- Headquarter Hong Kong, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website g-niib.com
- Social X Facebook Instagram
Competitors of G-NiiB
G-NiiB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, Geneoscopy, Pendulum and GenMark Diagnostics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| geneoscopy.com | 2015 | St. Louis, United States | $218.95M | – | Non-invasive biomarker tests for colorectal cancer are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| miroculus.com | 2014 | San Francisco, United States | $48.42M | – | MicroRNA profiling platform is developed to detect genes in samples. |
Detailed competitors of G-NiiB
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of G-NiiB
Websites that share an audience with G-NiiB (g-niib.com).
Websites whose visitors overlap most with G-NiiB. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biomed.hk | 89% | 5.9K | #3,739,655 | View details |
Latest news on G-Niib
Complete news archive for G-NiiB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to G-NiiB
10 companies that operate in the same segment as G-NiiB (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about G-NiiB
G-NiiB was founded in 2020.
G-NiiB is headquartered in Hong Kong, China.
G-NiiB develops innovative microbiome-based technologies for disease diagnostics and treatments, focusing on providing healthcare solutions, advancing biotech innovations, diagnostics and treatments, and microbiome technologies. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
G-NiiB's top competitors include Inflammatix, MeMed and Geneoscopy.